The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative

The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative

With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and pos...

Full description

Saved in:
Bibliographic Details
Published in:Journal francais d'ophtalmologie Vol. 41; no. 8; pp. 759 - 766
Main Authors: Ruiz-Medrano, J., Díaz-Valle, D., Cuiña, R., Gegúndez, J.A., Chhablani, J., Majumder, P.D., Gutierrez-Bonet, R.
Format: Journal Article
Language:English
Published: France Elsevier Masson SAS 01-10-2018
Subjects:
Agents biologiques
Antibodies, Monoclonal, Humanized - therapeutic use
Biologic agents
Eye Diseases - drug therapy
Humans
IL-6
Immunosuppressants
Immunosuppresseurs
Inflammation - drug therapy
Orbital Diseases - drug therapy
Tocilizumab
Treatment Outcome
Uveitis
Uvéites
Visual Acuity
Immunosuppressants
Uvéites
Tocilizumab
Uveitis
Biologic agents
Agents biologiques
Immunosuppresseurs
IL-6
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and possible uses of tocilizumab in the field of ophthalmology. We performed a search for records reporting the use of tocilizumab for various diseases in MEDLINE (PubMed and OVID). We conducted an analysis of several individual studies and their reported individual patient data (82 eyes of 45 patients) published from 2011 to 2017. Tocilizumab may prove to be an effective choice for the treatment of a variety of ocular conditions such as refractory uveitis, inflammatory macular edema, vitreo-retinal tumors and thyroid orbitopathy, leading to control of the inflammation in these patients. Further studies need to be conducted to establish its safety and efficacy. Les uvéites sont une des causes principales de cécité dans le monde, et les thérapies biologiques ont apparues comme une option pour le traitement des cas réfractaires en tenant compte des bons résultats obtenus dans la clinique. L’objectif de cette étude est de réaliser une révision systématique de la connaissance actuelle du rôle et des possibles applications du tocilizumab en ophtalmologie. Une recherche des rapports d’utilisation du tocilizumab pour des différentes maladies a été effectuée sur MEDLINE (PubMed et OVID). Une analyse de plusieurs études individuelles a été faite sur 82 yeux de 45 patients, publiés du 2011 au 2017. Le Tocilizumab peut être le traitement de choix pour certaines pathologies oculaires comme les uvéites réfractaires, l’œdème maculaire réfractaire, les tumeurs vitréo-rétiniennes et l’orbitopathie thyroïdienne, aidant à contrôler l’inflammation de ces patients. Des études complémentaire doivent être conduites pour établir l’efficacité et la sécurité de ce produit.
AbstractList With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and possible uses of tocilizumab in the field of ophthalmology. We performed a search for records reporting the use of tocilizumab for various diseases in MEDLINE (PubMed and OVID). We conducted an analysis of several individual studies and their reported individual patient data (82 eyes of 45 patients) published from 2011 to 2017. Tocilizumab may prove to be an effective choice for the treatment of a variety of ocular conditions such as refractory uveitis, inflammatory macular edema, vitreo-retinal tumors and thyroid orbitopathy, leading to control of the inflammation in these patients. Further studies need to be conducted to establish its safety and efficacy. Les uvéites sont une des causes principales de cécité dans le monde, et les thérapies biologiques ont apparues comme une option pour le traitement des cas réfractaires en tenant compte des bons résultats obtenus dans la clinique. L’objectif de cette étude est de réaliser une révision systématique de la connaissance actuelle du rôle et des possibles applications du tocilizumab en ophtalmologie. Une recherche des rapports d’utilisation du tocilizumab pour des différentes maladies a été effectuée sur MEDLINE (PubMed et OVID). Une analyse de plusieurs études individuelles a été faite sur 82 yeux de 45 patients, publiés du 2011 au 2017. Le Tocilizumab peut être le traitement de choix pour certaines pathologies oculaires comme les uvéites réfractaires, l’œdème maculaire réfractaire, les tumeurs vitréo-rétiniennes et l’orbitopathie thyroïdienne, aidant à contrôler l’inflammation de ces patients. Des études complémentaire doivent être conduites pour établir l’efficacité et la sécurité de ce produit.
With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based on good results shown in clinical practice. The goal of this study is to provide a systematic review of current knowledge of the role and possible uses of tocilizumab in the field of ophthalmology. We performed a search for records reporting the use of tocilizumab for various diseases in MEDLINE (PubMed and OVID). We conducted an analysis of several individual studies and their reported individual patient data (82 eyes of 45 patients) published from 2011 to 2017. Tocilizumab may prove to be an effective choice for the treatment of a variety of ocular conditions such as refractory uveitis, inflammatory macular edema, vitreo-retinal tumors and thyroid orbitopathy, leading to control of the inflammation in these patients. Further studies need to be conducted to establish its safety and efficacy.
Author Ruiz-Medrano, J.
Gutierrez-Bonet, R.
Majumder, P.D.
Díaz-Valle, D.
Gegúndez, J.A.
Cuiña, R.
Chhablani, J.
Author_xml – sequence: 1
  givenname: J.
  orcidid: 0000-0002-1105-9265
  surname: Ruiz-Medrano
  fullname: Ruiz-Medrano, J.
  email: jorge.ruizmedrano@gmail.com
  organization: Hospital Universitario Clínico San Carlos, Ophthalmology Unit, Madrid, Spain
– sequence: 2
  givenname: D.
  surname: Díaz-Valle
  fullname: Díaz-Valle, D.
  organization: Hospital Universitario Clínico San Carlos, Ophthalmology Unit, Madrid, Spain
– sequence: 3
  givenname: R.
  surname: Cuiña
  fullname: Cuiña, R.
  organization: Hospital Universitario Clínico San Carlos, Ophthalmology Unit, Madrid, Spain
– sequence: 4
  givenname: J.A.
  surname: Gegúndez
  fullname: Gegúndez, J.A.
  organization: Hospital Universitario Clínico San Carlos, Ophthalmology Unit, Madrid, Spain
– sequence: 5
  givenname: J.
  surname: Chhablani
  fullname: Chhablani, J.
  organization: L V Prasad Eye Institute, Hyderabad, India
– sequence: 6
  givenname: P.D.
  surname: Majumder
  fullname: Majumder, P.D.
  organization: Medical Research Foundation, Sankara Nethralaya, Chennai, India
– sequence: 7
  givenname: R.
  surname: Gutierrez-Bonet
  fullname: Gutierrez-Bonet, R.
  organization: Hospital Universitario Clínico San Carlos, Ophthalmology Unit, Madrid, Spain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30217605$$D View this record in MEDLINE/PubMed
BookMark eNp9kMtKAzEUhoMotl4ewI3kBWY8SZrOVFci3qDgRtchlxNMmZmUJBXq0zu16tLVWfz_93P4TsjhEAck5IJBzYDNr1b1yseaA2tr4DXA_IBMWdOICuSiOSTTMWCVlIxPyEnOKwAQjZTHZCKAs2YOckq613ekKXZIo6cl2tCFz02vDQ0DLWNUEurS41B2eRh8p_tel5i21IWMOmP-BscmbpHqwdGYTCjX9JZuMvpNR3VXMA26hA88I0dedxnPf-4peXu4f717qpYvj893t8vKCilK1YL3Vsv5gnM5841rBTPYGiFnOGOeO6O9k8YaCQ6MWOjWu1krQXNsLBNWilPC9rs2xZwTerVOoddpqxionTm1UqM5tTOngKvR3Mhc7pn1xvTo_ohfVWPhZl_A8fOPgEllG3Cw6EJCW5SL4Z_5LyW0ghc
CitedBy_id crossref_primary_10_1080_09273948_2019_1698754
crossref_primary_10_1016_j_jneuroim_2021_577573
crossref_primary_10_1159_000508237
crossref_primary_10_1097_IOP_0000000000002573
crossref_primary_10_1016_j_medcle_2020_10_016
crossref_primary_10_1186_s43166_021_00074_1
crossref_primary_10_1097_APO_0000000000000341
crossref_primary_10_1111_bcp_14459
crossref_primary_10_1016_j_medcli_2020_10_009
Cites_doi 10.1016/j.autrev.2012.07.012
10.3109/09273948.2011.619295
10.1016/j.ophtha.2014.06.050
10.1007/s10067-017-3672-z
10.3109/09273948.2011.606593
10.1016/j.ajo.2009.05.008
10.1016/j.ophtha.2012.05.048
10.1097/RHU.0b013e3181a4f459
10.1016/j.berh.2003.09.010
10.1016/j.ajo.2005.03.057
10.1182/blood-2004-12-4602
10.1089/thy.2007.0404
10.1016/j.ophtha.2009.04.020
10.1084/jem.174.3.561
10.1007/s00417-013-2436-y
10.1016/j.yexcr.2011.02.017
10.1038/nrd3800
10.1002/art.39940
10.1093/rheumatology/kev429
10.1210/jc.2014-3014
10.7150/ijbs.4666
10.1016/j.jbspin.2011.11.008
10.1016/j.ophtha.2013.09.048
10.1056/NEJMoa1205099
10.1016/S0002-9394(00)00659-0
10.1016/j.jfo.2012.01.002
10.1097/IAE.0b013e31828396cf
10.1016/S0140-6736(08)60454-7
10.1016/j.jaci.2012.09.034
10.1136/bjo.86.1.51
10.1136/ard.2003.014886
10.3109/09273948.2013.866254
10.1210/jc.2014-2572
10.1053/j.gastro.2004.01.012
10.1016/j.semarthrit.2013.01.003
10.1007/s00417-013-2466-5
10.1097/01.iio.0000155938.83083.94
10.1016/j.autrev.2013.02.002
10.1056/NEJMoa1112802
10.1002/art.10885
10.1016/S0140-6736(08)60453-5
10.1016/j.berh.2012.01.001
10.1016/j.semarthrit.2010.05.008
10.1093/rheumatology/keq343
10.1136/bjophthalmol-2012-302123
10.1007/s10792-013-9788-5
10.1016/j.ophtha.2009.06.060
10.1111/j.1365-2249.2006.03316.x
10.1111/aos.13015
10.1097/RHU.0b013e3181ba3c6f
10.1097/IOP.0000000000000037
10.1007/s00417-012-2243-x
10.1093/rheumatology/keq275
10.3899/jrheum.120010
10.1111/cei.12295
10.1007/s10067-011-1720-7
ContentType Journal Article
Copyright 2018 Elsevier Masson SAS
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: 2018 Elsevier Masson SAS
– notice: Copyright © 2018 Elsevier Masson SAS. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1016/j.jfo.2018.02.006
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Le rôle du tocilizumab pour le traitement des maladies oculaires inflammatoires : une alternative utile
EISSN 1773-0597
EndPage 766
ExternalDocumentID 10_1016_j_jfo_2018_02_006
30217605
S0181551218302821
Genre Journal Article
Review
GroupedDBID 08J
08T
0R~
4.4
457
53G
AAEDT
AALRI
AFNOS
AFTJW
AITUG
ALMA_UNASSIGNED_HOLDINGS
AOOFG
DIK
EBS
EJD
FDB
HZ~
O9-
SEM
SES
ABJNI
CGR
CUY
CVF
ECM
EIF
NPM
AAXUO
AAYXX
AFJKZ
AMRAJ
CITATION
ID FETCH-LOGICAL-c353t-80ffca5692254f7d831be8b354e41f2dbafd5bcb50d0b39a8fd4850a2e7c13c53
ISSN 0181-5512
IngestDate Thu Sep 26 17:51:54 EDT 2024
Fri Feb 23 03:38:24 EST 2024
Thu Jul 20 20:03:09 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Immunosuppressants
Uvéites
Tocilizumab
Uveitis
Biologic agents
Agents biologiques
Immunosuppresseurs
IL-6
Language English
License Copyright © 2018 Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c353t-80ffca5692254f7d831be8b354e41f2dbafd5bcb50d0b39a8fd4850a2e7c13c53
ORCID 0000-0002-1105-9265
PMID 30217605
PageCount 8
ParticipantIDs crossref_primary_10_1016_j_jfo_2018_02_006
pubmed_primary_30217605
elsevier_sciencedirect_doi_10_1016_j_jfo_2018_02_006
PublicationCentury 2000
PublicationDate October 2018
2018-Oct
2018-10-00
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: October 2018
PublicationDecade 2010
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Journal francais d'ophtalmologie
PublicationTitleAlternate J Fr Ophtalmol
PublicationYear 2018
Publisher Elsevier Masson SAS
Publisher_xml – name: Elsevier Masson SAS
References Ruperto, Brunner, Quartier (bib0595) 2012; 367
Campbell, Chen, Bhagat, Parker, Östör (bib0480) 2011; 50
Terrada, Bruneau, Perrenoud, Massin, Souied (bib0495) 2013; 35
Feito, Pereda (bib0385) 2009; 15
Feldmann, Brennan, Williams, Woody, Maini (bib0350) 2004; 18
Muselier, Bielefeld, Bidot, Vinit, Besancenot, Bron (bib0550) 2011; 21
Shima, Kuwahara, Murota (bib0410) 2010; 49
Calvo-Rio, Santos-Gomez, Calvo (bib0605) 2017; 69
Dinarello, Simon, van der Meer (bib0365) 2012; 11
Smolen, Beaulieu, Rubbert-Roth (bib0425) 2008; 371
Brézin, Monnet, Cohen, Levinson (bib0485) 2011; 19
Mesquida, Molins, Llorenç, Sainz de la Maza, Adan (bib0545) 2014; 121
Oshitari, Kajita, Tobe (bib0540) 2012; 2012
Adan, Llorenç, Mesquida, Pelegrin (bib0475) 2013; 251
Burkholder, Wang, Dunn, Nguyen, Thorne (bib0500) 2013; 33
Greco, Gallo, Fusconi, Magliulo, Turchetta, Marinelli (bib0395) 2013; 12
Yokota, Imagawa, Mori (bib0435) 2008; 371
Adán, Mesquida, Llorenç, Espinosa, Molins, Hernández (bib0470) 2013; 251
Alexeeva, Valieva, Bzarova, Semikina, Isaeva, Lisitsyn (bib0380) 2011; 30
De Benedetti, Brunner, Ruperto (bib0590) 2012; 367
Edelsten, Lee, Bentley, Kanski, Graham (bib0525) 2002; 86
Lopalco, Fabiani, Sota (bib0520) 2017; 36
Pérez-Moreiras, Álvarez-López, Cardiel (bib0570) 2014; 30
Adler, Kolev, Varisco (bib0440) 2013; 131
Salvi, Vannucchi, Currò (bib0580) 2015; 100
Jabs, Rosenbaum, Foster, Holland, Jaffe, Louie (bib0330) 2000; 130
Douglas, Gianoukakis, Goldberg (bib0565) 2007; 148
Wakefield, Chang (bib0325) 2005; 45
Linsley, Brady, Urnes, Grosmaire, Damle, Ledbetter (bib0375) 1991; 174
Quartier, Taupin, Bourdeaut, Lemelle, Pillet, Bost (bib0355) 2003; 48
Cervantes-Castañeda, Gonzalez-Gonzalez, Cordero-Coma, Yilmaz, Foster (bib0490) 2013; 97
Kaly, Rosner (bib0390) 2012; 26
Tsang, Roth, Gottlieb (bib0460) 2014; 22
Adán, Mesquida, Llorenç, Modesto (bib0465) 2014; 252
Zeft, Hollister, LaFleur, Sampath, Soep, McNally (bib0370) 2009; 15
Nishimoto, Kanakura, Aozasa (bib0430) 2005; 106
Seitz, Reichembach, Bonel, Adler, Wermelinger, Villiger (bib0535) 2011; 141
Gangaputra, Newcomb, Liesegang (bib0340) 2009; 116
Mesquida, Leszczynska, Llorenç, Adan (bib0405) 2014; 176
Kearsley-Fleet, Davies, Baildam (bib0615) 2016; 55
Horneff, Schmeling, Biedermann, Foeldvari, Ganser, Girschick (bib0360) 2004; 63
Tanaka, Kishimoto (bib0400) 2012; 8
Saadoun, Bodaghi, Bienvenu, Wechsler, Sene, Trad (bib0510) 2013; 12
Mircic, Kavanaugh (bib0530) 2011; 317
Levy-Clarke, Jabs, Read, Rosenbaum, Vitale, Van Gelder (bib0600) 2014; 121
Smith, Tsai, Shih (bib0560) 2008; 18
(bib0630) 2015
Pasadhika, Rosenbaum (bib0450) 2014; 8
Pujari, Kempen, Newcomb (bib0345) 2010; 117
Vinit, Bielefeld, Muller, Besancenot (bib0625) 2012; 79
Artornsombudh, Gevorgyan, Payal, Siddique, Foster (bib0505) 2013; 120
Tappeiner, Heinz, Ganser, Heiligenhaus (bib0455) 2012; 39
Fukuda (bib0420) 2004; 126
Stan, Garrity, Carranza Leon, Prabin, Bradley, Bahn (bib0585) 2015; 100
Pato, Muñoz-Fernández, Francisco, Abad, Maese, Ortiz (bib0445) 2011; 40
Papo, Bielefeld, Vallet (bib0555) 2014; 32
Menezo, Taylor (bib0515) 2014; 8
Mesquida, Molins, Llorenç (bib0415) 2014; 34
Macchioni, Boiardi, Catanoso (bib0620) 2013; 43
Pasadhika, Kempen, Newcomb (bib0335) 2009; 148
Smolen, Beaulieu, Rubbert-Roth (bib0575) 2008; 371
Silpa-archa, Oray, Preble, Foster (bib0610) 2016; 94
Jabs, Nussenblatt, Rosenbaum (bib0320) 2005; 140
Menezo (10.1016/j.jfo.2018.02.006_bib0515) 2014; 8
Burkholder (10.1016/j.jfo.2018.02.006_bib0500) 2013; 33
Linsley (10.1016/j.jfo.2018.02.006_bib0375) 1991; 174
Gangaputra (10.1016/j.jfo.2018.02.006_bib0340) 2009; 116
Adán (10.1016/j.jfo.2018.02.006_bib0465) 2014; 252
Smolen (10.1016/j.jfo.2018.02.006_bib0575) 2008; 371
Saadoun (10.1016/j.jfo.2018.02.006_bib0510) 2013; 12
Quartier (10.1016/j.jfo.2018.02.006_bib0355) 2003; 48
Muselier (10.1016/j.jfo.2018.02.006_bib0550) 2011; 21
Horneff (10.1016/j.jfo.2018.02.006_bib0360) 2004; 63
Papo (10.1016/j.jfo.2018.02.006_bib0555) 2014; 32
Mesquida (10.1016/j.jfo.2018.02.006_bib0415) 2014; 34
Ruperto (10.1016/j.jfo.2018.02.006_bib0595) 2012; 367
Pasadhika (10.1016/j.jfo.2018.02.006_bib0450) 2014; 8
Brézin (10.1016/j.jfo.2018.02.006_bib0485) 2011; 19
Kearsley-Fleet (10.1016/j.jfo.2018.02.006_bib0615) 2016; 55
(10.1016/j.jfo.2018.02.006_bib0630) 2015
Seitz (10.1016/j.jfo.2018.02.006_bib0535) 2011; 141
Mesquida (10.1016/j.jfo.2018.02.006_bib0405) 2014; 176
Adan (10.1016/j.jfo.2018.02.006_bib0475) 2013; 251
Calvo-Rio (10.1016/j.jfo.2018.02.006_bib0605) 2017; 69
Edelsten (10.1016/j.jfo.2018.02.006_bib0525) 2002; 86
Feito (10.1016/j.jfo.2018.02.006_bib0385) 2009; 15
Jabs (10.1016/j.jfo.2018.02.006_bib0320) 2005; 140
Adán (10.1016/j.jfo.2018.02.006_bib0470) 2013; 251
Zeft (10.1016/j.jfo.2018.02.006_bib0370) 2009; 15
Shima (10.1016/j.jfo.2018.02.006_bib0410) 2010; 49
Cervantes-Castañeda (10.1016/j.jfo.2018.02.006_bib0490) 2013; 97
Tsang (10.1016/j.jfo.2018.02.006_bib0460) 2014; 22
Tappeiner (10.1016/j.jfo.2018.02.006_bib0455) 2012; 39
Feldmann (10.1016/j.jfo.2018.02.006_bib0350) 2004; 18
Pato (10.1016/j.jfo.2018.02.006_bib0445) 2011; 40
Levy-Clarke (10.1016/j.jfo.2018.02.006_bib0600) 2014; 121
Douglas (10.1016/j.jfo.2018.02.006_bib0565) 2007; 148
Greco (10.1016/j.jfo.2018.02.006_bib0395) 2013; 12
Tanaka (10.1016/j.jfo.2018.02.006_bib0400) 2012; 8
Terrada (10.1016/j.jfo.2018.02.006_bib0495) 2013; 35
Smith (10.1016/j.jfo.2018.02.006_bib0560) 2008; 18
Pujari (10.1016/j.jfo.2018.02.006_bib0345) 2010; 117
Smolen (10.1016/j.jfo.2018.02.006_bib0425) 2008; 371
Stan (10.1016/j.jfo.2018.02.006_bib0585) 2015; 100
Mesquida (10.1016/j.jfo.2018.02.006_bib0545) 2014; 121
Silpa-archa (10.1016/j.jfo.2018.02.006_bib0610) 2016; 94
Jabs (10.1016/j.jfo.2018.02.006_bib0330) 2000; 130
Lopalco (10.1016/j.jfo.2018.02.006_bib0520) 2017; 36
Wakefield (10.1016/j.jfo.2018.02.006_bib0325) 2005; 45
Mircic (10.1016/j.jfo.2018.02.006_bib0530) 2011; 317
Salvi (10.1016/j.jfo.2018.02.006_bib0580) 2015; 100
Dinarello (10.1016/j.jfo.2018.02.006_bib0365) 2012; 11
Adler (10.1016/j.jfo.2018.02.006_bib0440) 2013; 131
Macchioni (10.1016/j.jfo.2018.02.006_bib0620) 2013; 43
Alexeeva (10.1016/j.jfo.2018.02.006_bib0380) 2011; 30
Nishimoto (10.1016/j.jfo.2018.02.006_bib0430) 2005; 106
De Benedetti (10.1016/j.jfo.2018.02.006_bib0590) 2012; 367
Kaly (10.1016/j.jfo.2018.02.006_bib0390) 2012; 26
Fukuda (10.1016/j.jfo.2018.02.006_bib0420) 2004; 126
Oshitari (10.1016/j.jfo.2018.02.006_bib0540) 2012; 2012
Pasadhika (10.1016/j.jfo.2018.02.006_bib0335) 2009; 148
Campbell (10.1016/j.jfo.2018.02.006_bib0480) 2011; 50
Vinit (10.1016/j.jfo.2018.02.006_bib0625) 2012; 79
Yokota (10.1016/j.jfo.2018.02.006_bib0435) 2008; 371
Pérez-Moreiras (10.1016/j.jfo.2018.02.006_bib0570) 2014; 30
Artornsombudh (10.1016/j.jfo.2018.02.006_bib0505) 2013; 120
References_xml – volume: 140
  start-page: 509
  year: 2005
  end-page: 516
  ident: bib0320
  article-title: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Rosenbaum
– volume: 18
  start-page: 59
  year: 2004
  end-page: 80
  ident: bib0350
  article-title: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
  publication-title: Best Pract Res Clin Rheumatol
  contributor:
    fullname: Maini
– volume: 79
  start-page: 317
  year: 2012
  end-page: 318
  ident: bib0625
  article-title: Efficacy of tocilizumab in refractory giant cell arteritis
  publication-title: Joint Bone Spine
  contributor:
    fullname: Besancenot
– volume: 21
  start-page: 382
  year: 2011
  end-page: 383
  ident: bib0550
  article-title: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis
  publication-title: Ocular Immunol Inflamm
  contributor:
    fullname: Bron
– volume: 8
  start-page: 1227
  year: 2012
  end-page: 1236
  ident: bib0400
  article-title: Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases
  publication-title: Int J Biol Sci
  contributor:
    fullname: Kishimoto
– volume: 176
  start-page: 301
  year: 2014
  end-page: 309
  ident: bib0405
  article-title: Interleukin-6 blockade in ocular inflammatory diseases
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Adan
– volume: 15
  start-page: 363
  year: 2009
  end-page: 365
  ident: bib0385
  article-title: Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists
  publication-title: J Clin Rheumatol
  contributor:
    fullname: Pereda
– volume: 69
  start-page: 668
  year: 2017
  end-page: 675
  ident: bib0605
  article-title: Anti-Interleukin-6 receptor tocilizumab for juvenile idiopathic arthritis-associated uveítis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients
  publication-title: Arthritis rheumatol
  contributor:
    fullname: Calvo
– volume: 121
  start-page: 785
  year: 2014
  end-page: 796
  ident: bib0600
  article-title: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders
  publication-title: Ophthalmology
  contributor:
    fullname: Van Gelder
– year: 2015
  ident: bib0630
  article-title: Tocilizumab for patients with giant cell arteritis
– volume: 36
  start-page: 1459
  year: 2017
  end-page: 1469
  ident: bib0520
  article-title: IL-6 blockade in the management of non-infectious uveitis
  publication-title: Clin Rheumatol
  contributor:
    fullname: Sota
– volume: 12
  start-page: 774
  year: 2013
  end-page: 783
  ident: bib0510
  article-title: Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies
  publication-title: Autoimmun Rev
  contributor:
    fullname: Trad
– volume: 106
  start-page: 2627
  year: 2005
  end-page: 2632
  ident: bib0430
  article-title: Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease
  publication-title: Blood
  contributor:
    fullname: Aozasa
– volume: 11
  start-page: 633
  year: 2012
  end-page: 652
  ident: bib0365
  article-title: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
  publication-title: Nat Rev Drug Discov
  contributor:
    fullname: van der Meer
– volume: 130
  start-page: 492
  year: 2000
  end-page: 513
  ident: bib0330
  article-title: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Louie
– volume: 32
  start-page: S75
  year: 2014
  end-page: S79
  ident: bib0555
  article-title: Tocilizumab in severe and refractory non-infectious uveitis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Vallet
– volume: 116
  start-page: 2188
  year: 2009
  end-page: 2198
  ident: bib0340
  article-title: Methotrexate for ocular inflammatory diseases
  publication-title: Ophthalmology
  contributor:
    fullname: Liesegang
– volume: 367
  start-page: 2385
  year: 2012
  end-page: 2395
  ident: bib0590
  article-title: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
  publication-title: N Engl J Med
  contributor:
    fullname: Ruperto
– volume: 126
  start-page: 989
  year: 2004
  end-page: 996
  ident: bib0420
  article-title: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
  publication-title: Gastroenterology
  contributor:
    fullname: Fukuda
– volume: 33
  start-page: 1684
  year: 2013
  end-page: 1693
  ident: bib0500
  article-title: Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis
  publication-title: Retina
  contributor:
    fullname: Thorne
– volume: 40
  start-page: 314
  year: 2011
  end-page: 323
  ident: bib0445
  article-title: Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis
  publication-title: Semin Arthritis Rheum
  contributor:
    fullname: Ortiz
– volume: 26
  start-page: 157
  year: 2012
  end-page: 165
  ident: bib0390
  article-title: Tocilizumab – a novel therapy for non-organ-specific autoimmune diseases
  publication-title: Best Pract Res Clin Rheumatol
  contributor:
    fullname: Rosner
– volume: 131
  start-page: 1235
  year: 2013
  end-page: 1237
  ident: bib0440
  article-title: Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy
  publication-title: J Allergy Clin Immunol
  contributor:
    fullname: Varisco
– volume: 22
  start-page: 155
  year: 2014
  end-page: 157
  ident: bib0460
  article-title: Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient
  publication-title: Ocul Immunol Inflamm
  contributor:
    fullname: Gottlieb
– volume: 49
  start-page: 2408
  year: 2010
  end-page: 2412
  ident: bib0410
  article-title: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
  publication-title: Rheumatology (Oxf)
  contributor:
    fullname: Murota
– volume: 100
  start-page: 422
  year: 2015
  end-page: 431
  ident: bib0580
  article-title: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study
  publication-title: J Clin Endocrinol Metab
  contributor:
    fullname: Currò
– volume: 120
  start-page: 588
  year: 2013
  end-page: 592
  ident: bib0505
  article-title: Infliximab treatment of patients with birdshot retinochoroidopathy
  publication-title: Ophthalmology
  contributor:
    fullname: Foster
– volume: 251
  start-page: 2249
  year: 2013
  end-page: 2250
  ident: bib0475
  article-title: Tocilizumab treatment for recalcitrant uveitic macular edema
  publication-title: Graefes Arch Clin Exp Ophthalmol
  contributor:
    fullname: Pelegrin
– volume: 86
  start-page: 51
  year: 2002
  end-page: 56
  ident: bib0525
  article-title: An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis in early childhood
  publication-title: Br J Ophthalmol
  contributor:
    fullname: Graham
– volume: 317
  start-page: 1286
  year: 2011
  end-page: 1292
  ident: bib0530
  article-title: Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis
  publication-title: Exp Cell Res
  contributor:
    fullname: Kavanaugh
– volume: 2012
  start-page: 968180
  year: 2012
  ident: bib0540
  article-title: Refractory uveitis in patient with castleman disease successfully treated with tocilizumab
  publication-title: Case Rep Ophthalmol Med
  contributor:
    fullname: Tobe
– volume: 371
  start-page: 998
  year: 2008
  end-page: 1006
  ident: bib0435
  article-title: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial
  publication-title: Lancet
  contributor:
    fullname: Mori
– volume: 251
  start-page: 2627
  year: 2013
  end-page: 2632
  ident: bib0470
  article-title: Tocilizumab treatment for refractory uveitis-related cystoid macular edema
  publication-title: Graefes Arch Clin Exp Ophthalmol
  contributor:
    fullname: Hernández
– volume: 252
  start-page: 163
  year: 2014
  end-page: 164
  ident: bib0465
  article-title: Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report
  publication-title: Graefes Arch Clin Exp Ophthalmol
  contributor:
    fullname: Modesto
– volume: 121
  start-page: 2380
  year: 2014
  end-page: 2386
  ident: bib0545
  article-title: Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema
  publication-title: Ophthalmology
  contributor:
    fullname: Adan
– volume: 15
  start-page: 161
  year: 2009
  end-page: 164
  ident: bib0370
  article-title: Anakinra for systemic juvenile arthritis: the Rocky Mountain experience
  publication-title: J Clin Rheumatol
  contributor:
    fullname: McNally
– volume: 19
  start-page: 397
  year: 2011
  end-page: 400
  ident: bib0485
  article-title: HLA-A29 and birdshot chorioretinopathy
  publication-title: Ocul Immunol Inflamm
  contributor:
    fullname: Levinson
– volume: 100
  start-page: 432
  year: 2015
  end-page: 441
  ident: bib0585
  article-title: Randomized controlled trial of rituximab in patients with Graves’ orbitopathy
  publication-title: J Clin Endocrinol Metab
  contributor:
    fullname: Bahn
– volume: 55
  start-page: 1556
  year: 2016
  end-page: 1565
  ident: bib0615
  article-title: Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers
  publication-title: Rheumatology
  contributor:
    fullname: Baildam
– volume: 43
  start-page: 113
  year: 2013
  end-page: 118
  ident: bib0620
  article-title: Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature
  publication-title: Semin Arthritis Rheum
  contributor:
    fullname: Catanoso
– volume: 117
  start-page: 356
  year: 2010
  end-page: 365
  ident: bib0345
  article-title: Cyclophosphamide for ocular inflammatory diseases
  publication-title: Ophthalmology
  contributor:
    fullname: Newcomb
– volume: 141
  year: 2011
  ident: bib0535
  article-title: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
  publication-title: Swiss Med Wkly
  contributor:
    fullname: Villiger
– volume: 174
  start-page: 561
  year: 1991
  end-page: 569
  ident: bib0375
  article-title: CTLA-4 is a second receptor for the B cell activation antigen B7
  publication-title: J Exp Med
  contributor:
    fullname: Ledbetter
– volume: 371
  start-page: 987
  year: 2008
  end-page: 997
  ident: bib0575
  article-title: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
  publication-title: Lancet
  contributor:
    fullname: Rubbert-Roth
– volume: 34
  start-page: 365
  year: 2014
  end-page: 381
  ident: bib0415
  article-title: Current and future treatments for Behçet's uveitis: road to remission
  publication-title: Int Ophthalmol
  contributor:
    fullname: Llorenç
– volume: 30
  start-page: 162
  year: 2014
  end-page: 167
  ident: bib0570
  article-title: Treatment of active corticosteroid-resistant graves’orbitopathy
  publication-title: Ophthal Plast Reconstr Surg
  contributor:
    fullname: Cardiel
– volume: 45
  start-page: 1
  year: 2005
  end-page: 13
  ident: bib0325
  article-title: Epidemiology of uveitis
  publication-title: Int Ophthalmol Clin
  contributor:
    fullname: Chang
– volume: 39
  start-page: 1294
  year: 2012
  end-page: 1295
  ident: bib0455
  article-title: Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
  publication-title: J Rheumatol
  contributor:
    fullname: Heiligenhaus
– volume: 18
  start-page: 983
  year: 2008
  end-page: 988
  ident: bib0560
  article-title: Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy
  publication-title: Thyroid
  contributor:
    fullname: Shih
– volume: 97
  start-page: 637
  year: 2013
  end-page: 643
  ident: bib0490
  article-title: Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up
  publication-title: Br J Ophthalmol
  contributor:
    fullname: Foster
– volume: 94
  start-page: e400
  year: 2016
  end-page: e406
  ident: bib0610
  article-title: Outcome of tocilizumab treatment in refractory ocular inflammatory diseases
  publication-title: Acta Ophthalmol
  contributor:
    fullname: Foster
– volume: 8
  start-page: 73
  year: 2014
  end-page: 81
  ident: bib0515
  article-title: Birdshot uveitis: current and emerging treatment options
  publication-title: Clin Ophthalmol
  contributor:
    fullname: Taylor
– volume: 371
  start-page: 987
  year: 2008
  end-page: 997
  ident: bib0425
  article-title: OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial
  publication-title: Lancet
  contributor:
    fullname: Rubbert-Roth
– volume: 50
  start-page: 552
  year: 2011
  end-page: 562
  ident: bib0480
  article-title: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
  publication-title: Rheumatology (Oxf)
  contributor:
    fullname: Östör
– volume: 148
  start-page: 500
  year: 2009
  end-page: 509
  ident: bib0335
  article-title: Azathioprine for ocular inflammatory diseases
  publication-title: Am J Ophthalmol
  contributor:
    fullname: Newcomb
– volume: 35
  start-page: 745
  year: 2013
  end-page: 748
  ident: bib0495
  article-title: Role of intravitreal dexamethasone implant in the treatment of birdshot retinochoroidopathy
  publication-title: J Fr Ophtalmol
  contributor:
    fullname: Souied
– volume: 12
  start-page: 396
  year: 2013
  end-page: 400
  ident: bib0395
  article-title: Cogan's syndrome: an autoimmune inner ear disease
  publication-title: Autoimmun Rev
  contributor:
    fullname: Marinelli
– volume: 8
  start-page: 67
  year: 2014
  end-page: 81
  ident: bib0450
  article-title: Update on the use of systemic biologic agents in the treatment of noninfectious uveitis
  publication-title: Biologics
  contributor:
    fullname: Rosenbaum
– volume: 63
  start-page: 1638
  year: 2004
  end-page: 1644
  ident: bib0360
  article-title: The German etanercept registry for treatment of juvenile idiopathic arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Girschick
– volume: 148
  start-page: 64
  year: 2007
  end-page: 71
  ident: bib0565
  article-title: Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Goldberg
– volume: 48
  start-page: 1093
  year: 2003
  end-page: 1101
  ident: bib0355
  article-title: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
  publication-title: Arthritis Rheum
  contributor:
    fullname: Bost
– volume: 30
  start-page: 1163
  year: 2011
  end-page: 1172
  ident: bib0380
  article-title: Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis
  publication-title: Clin Rheumatol
  contributor:
    fullname: Lisitsyn
– volume: 367
  start-page: 2396
  year: 2012
  end-page: 2406
  ident: bib0595
  article-title: Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
  publication-title: N Engl J Med
  contributor:
    fullname: Quartier
– volume: 12
  start-page: 396
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0395
  article-title: Cogan's syndrome: an autoimmune inner ear disease
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2012.07.012
  contributor:
    fullname: Greco
– volume: 19
  start-page: 397
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0485
  article-title: HLA-A29 and birdshot chorioretinopathy
  publication-title: Ocul Immunol Inflamm
  doi: 10.3109/09273948.2011.619295
  contributor:
    fullname: Brézin
– volume: 121
  start-page: 2380
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0545
  article-title: Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2014.06.050
  contributor:
    fullname: Mesquida
– volume: 36
  start-page: 1459
  year: 2017
  ident: 10.1016/j.jfo.2018.02.006_bib0520
  article-title: IL-6 blockade in the management of non-infectious uveitis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-017-3672-z
  contributor:
    fullname: Lopalco
– volume: 21
  start-page: 382
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0550
  article-title: Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis
  publication-title: Ocular Immunol Inflamm
  doi: 10.3109/09273948.2011.606593
  contributor:
    fullname: Muselier
– volume: 148
  start-page: 500
  year: 2009
  ident: 10.1016/j.jfo.2018.02.006_bib0335
  article-title: Azathioprine for ocular inflammatory diseases
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2009.05.008
  contributor:
    fullname: Pasadhika
– volume: 120
  start-page: 588
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0505
  article-title: Infliximab treatment of patients with birdshot retinochoroidopathy
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2012.05.048
  contributor:
    fullname: Artornsombudh
– volume: 15
  start-page: 161
  year: 2009
  ident: 10.1016/j.jfo.2018.02.006_bib0370
  article-title: Anakinra for systemic juvenile arthritis: the Rocky Mountain experience
  publication-title: J Clin Rheumatol
  doi: 10.1097/RHU.0b013e3181a4f459
  contributor:
    fullname: Zeft
– volume: 18
  start-page: 59
  year: 2004
  ident: 10.1016/j.jfo.2018.02.006_bib0350
  article-title: The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2003.09.010
  contributor:
    fullname: Feldmann
– volume: 141
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0535
  article-title: Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
  publication-title: Swiss Med Wkly
  contributor:
    fullname: Seitz
– volume: 140
  start-page: 509
  year: 2005
  ident: 10.1016/j.jfo.2018.02.006_bib0320
  article-title: Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2005.03.057
  contributor:
    fullname: Jabs
– volume: 106
  start-page: 2627
  year: 2005
  ident: 10.1016/j.jfo.2018.02.006_bib0430
  article-title: Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease
  publication-title: Blood
  doi: 10.1182/blood-2004-12-4602
  contributor:
    fullname: Nishimoto
– volume: 18
  start-page: 983
  year: 2008
  ident: 10.1016/j.jfo.2018.02.006_bib0560
  article-title: Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy
  publication-title: Thyroid
  doi: 10.1089/thy.2007.0404
  contributor:
    fullname: Smith
– volume: 116
  start-page: 2188
  year: 2009
  ident: 10.1016/j.jfo.2018.02.006_bib0340
  article-title: Methotrexate for ocular inflammatory diseases
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.04.020
  contributor:
    fullname: Gangaputra
– volume: 174
  start-page: 561
  year: 1991
  ident: 10.1016/j.jfo.2018.02.006_bib0375
  article-title: CTLA-4 is a second receptor for the B cell activation antigen B7
  publication-title: J Exp Med
  doi: 10.1084/jem.174.3.561
  contributor:
    fullname: Linsley
– volume: 251
  start-page: 2627
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0470
  article-title: Tocilizumab treatment for refractory uveitis-related cystoid macular edema
  publication-title: Graefes Arch Clin Exp Ophthalmol
  doi: 10.1007/s00417-013-2436-y
  contributor:
    fullname: Adán
– year: 2015
  ident: 10.1016/j.jfo.2018.02.006_bib0630
– volume: 317
  start-page: 1286
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0530
  article-title: Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2011.02.017
  contributor:
    fullname: Mircic
– volume: 11
  start-page: 633
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0365
  article-title: Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3800
  contributor:
    fullname: Dinarello
– volume: 69
  start-page: 668
  year: 2017
  ident: 10.1016/j.jfo.2018.02.006_bib0605
  article-title: Anti-Interleukin-6 receptor tocilizumab for juvenile idiopathic arthritis-associated uveítis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients
  publication-title: Arthritis rheumatol
  doi: 10.1002/art.39940
  contributor:
    fullname: Calvo-Rio
– volume: 32
  start-page: S75
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0555
  article-title: Tocilizumab in severe and refractory non-infectious uveitis
  publication-title: Clin Exp Rheumatol
  contributor:
    fullname: Papo
– volume: 55
  start-page: 1556
  year: 2016
  ident: 10.1016/j.jfo.2018.02.006_bib0615
  article-title: Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kev429
  contributor:
    fullname: Kearsley-Fleet
– volume: 100
  start-page: 422
  year: 2015
  ident: 10.1016/j.jfo.2018.02.006_bib0580
  article-title: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-3014
  contributor:
    fullname: Salvi
– volume: 8
  start-page: 1227
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0400
  article-title: Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.4666
  contributor:
    fullname: Tanaka
– volume: 79
  start-page: 317
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0625
  article-title: Efficacy of tocilizumab in refractory giant cell arteritis
  publication-title: Joint Bone Spine
  doi: 10.1016/j.jbspin.2011.11.008
  contributor:
    fullname: Vinit
– volume: 121
  start-page: 785
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0600
  article-title: Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2013.09.048
  contributor:
    fullname: Levy-Clarke
– volume: 367
  start-page: 2396
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0595
  article-title: Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1205099
  contributor:
    fullname: Ruperto
– volume: 130
  start-page: 492
  year: 2000
  ident: 10.1016/j.jfo.2018.02.006_bib0330
  article-title: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
  publication-title: Am J Ophthalmol
  doi: 10.1016/S0002-9394(00)00659-0
  contributor:
    fullname: Jabs
– volume: 35
  start-page: 745
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0495
  article-title: Role of intravitreal dexamethasone implant in the treatment of birdshot retinochoroidopathy
  publication-title: J Fr Ophtalmol
  doi: 10.1016/j.jfo.2012.01.002
  contributor:
    fullname: Terrada
– volume: 33
  start-page: 1684
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0500
  article-title: Postoperative outcomes after fluocinolone acetonide implant surgery in patients with birdshot chorioretinitis and other types of posterior and panuveitis
  publication-title: Retina
  doi: 10.1097/IAE.0b013e31828396cf
  contributor:
    fullname: Burkholder
– volume: 371
  start-page: 998
  year: 2008
  ident: 10.1016/j.jfo.2018.02.006_bib0435
  article-title: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)60454-7
  contributor:
    fullname: Yokota
– volume: 8
  start-page: 73
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0515
  article-title: Birdshot uveitis: current and emerging treatment options
  publication-title: Clin Ophthalmol
  contributor:
    fullname: Menezo
– volume: 131
  start-page: 1235
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0440
  article-title: Induction of severe systemic lupus erythematosus by TNF blockade and response to anti-IL-6 strategy
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2012.09.034
  contributor:
    fullname: Adler
– volume: 86
  start-page: 51
  year: 2002
  ident: 10.1016/j.jfo.2018.02.006_bib0525
  article-title: An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis in early childhood
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.86.1.51
  contributor:
    fullname: Edelsten
– volume: 63
  start-page: 1638
  year: 2004
  ident: 10.1016/j.jfo.2018.02.006_bib0360
  article-title: The German etanercept registry for treatment of juvenile idiopathic arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2003.014886
  contributor:
    fullname: Horneff
– volume: 22
  start-page: 155
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0460
  article-title: Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient
  publication-title: Ocul Immunol Inflamm
  doi: 10.3109/09273948.2013.866254
  contributor:
    fullname: Tsang
– volume: 100
  start-page: 432
  year: 2015
  ident: 10.1016/j.jfo.2018.02.006_bib0585
  article-title: Randomized controlled trial of rituximab in patients with Graves’ orbitopathy
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2014-2572
  contributor:
    fullname: Stan
– volume: 126
  start-page: 989
  year: 2004
  ident: 10.1016/j.jfo.2018.02.006_bib0420
  article-title: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.01.012
  contributor:
    fullname: Fukuda
– volume: 43
  start-page: 113
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0620
  article-title: Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2013.01.003
  contributor:
    fullname: Macchioni
– volume: 252
  start-page: 163
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0465
  article-title: Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report
  publication-title: Graefes Arch Clin Exp Ophthalmol
  doi: 10.1007/s00417-013-2466-5
  contributor:
    fullname: Adán
– volume: 8
  start-page: 67
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0450
  article-title: Update on the use of systemic biologic agents in the treatment of noninfectious uveitis
  publication-title: Biologics
  contributor:
    fullname: Pasadhika
– volume: 45
  start-page: 1
  year: 2005
  ident: 10.1016/j.jfo.2018.02.006_bib0325
  article-title: Epidemiology of uveitis
  publication-title: Int Ophthalmol Clin
  doi: 10.1097/01.iio.0000155938.83083.94
  contributor:
    fullname: Wakefield
– volume: 12
  start-page: 774
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0510
  article-title: Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2013.02.002
  contributor:
    fullname: Saadoun
– volume: 367
  start-page: 2385
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0590
  article-title: Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1112802
  contributor:
    fullname: De Benedetti
– volume: 48
  start-page: 1093
  year: 2003
  ident: 10.1016/j.jfo.2018.02.006_bib0355
  article-title: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
  publication-title: Arthritis Rheum
  doi: 10.1002/art.10885
  contributor:
    fullname: Quartier
– volume: 2012
  start-page: 968180
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0540
  article-title: Refractory uveitis in patient with castleman disease successfully treated with tocilizumab
  publication-title: Case Rep Ophthalmol Med
  contributor:
    fullname: Oshitari
– volume: 371
  start-page: 987
  year: 2008
  ident: 10.1016/j.jfo.2018.02.006_bib0575
  article-title: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)60453-5
  contributor:
    fullname: Smolen
– volume: 26
  start-page: 157
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0390
  article-title: Tocilizumab – a novel therapy for non-organ-specific autoimmune diseases
  publication-title: Best Pract Res Clin Rheumatol
  doi: 10.1016/j.berh.2012.01.001
  contributor:
    fullname: Kaly
– volume: 371
  start-page: 987
  year: 2008
  ident: 10.1016/j.jfo.2018.02.006_bib0425
  article-title: OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)60453-5
  contributor:
    fullname: Smolen
– volume: 40
  start-page: 314
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0445
  article-title: Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2010.05.008
  contributor:
    fullname: Pato
– volume: 50
  start-page: 552
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0480
  article-title: Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
  publication-title: Rheumatology (Oxf)
  doi: 10.1093/rheumatology/keq343
  contributor:
    fullname: Campbell
– volume: 97
  start-page: 637
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0490
  article-title: Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjophthalmol-2012-302123
  contributor:
    fullname: Cervantes-Castañeda
– volume: 34
  start-page: 365
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0415
  article-title: Current and future treatments for Behçet's uveitis: road to remission
  publication-title: Int Ophthalmol
  doi: 10.1007/s10792-013-9788-5
  contributor:
    fullname: Mesquida
– volume: 117
  start-page: 356
  year: 2010
  ident: 10.1016/j.jfo.2018.02.006_bib0345
  article-title: Cyclophosphamide for ocular inflammatory diseases
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2009.06.060
  contributor:
    fullname: Pujari
– volume: 148
  start-page: 64
  year: 2007
  ident: 10.1016/j.jfo.2018.02.006_bib0565
  article-title: Circulating mononuclear cells from euthyroid patients with thyroid-associated ophthalmopathy exhibit characteristic phenotypes
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.2006.03316.x
  contributor:
    fullname: Douglas
– volume: 94
  start-page: e400
  year: 2016
  ident: 10.1016/j.jfo.2018.02.006_bib0610
  article-title: Outcome of tocilizumab treatment in refractory ocular inflammatory diseases
  publication-title: Acta Ophthalmol
  doi: 10.1111/aos.13015
  contributor:
    fullname: Silpa-archa
– volume: 15
  start-page: 363
  year: 2009
  ident: 10.1016/j.jfo.2018.02.006_bib0385
  article-title: Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists
  publication-title: J Clin Rheumatol
  doi: 10.1097/RHU.0b013e3181ba3c6f
  contributor:
    fullname: Feito
– volume: 30
  start-page: 162
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0570
  article-title: Treatment of active corticosteroid-resistant graves’orbitopathy
  publication-title: Ophthal Plast Reconstr Surg
  doi: 10.1097/IOP.0000000000000037
  contributor:
    fullname: Pérez-Moreiras
– volume: 251
  start-page: 2249
  year: 2013
  ident: 10.1016/j.jfo.2018.02.006_bib0475
  article-title: Tocilizumab treatment for recalcitrant uveitic macular edema
  publication-title: Graefes Arch Clin Exp Ophthalmol
  doi: 10.1007/s00417-012-2243-x
  contributor:
    fullname: Adan
– volume: 49
  start-page: 2408
  year: 2010
  ident: 10.1016/j.jfo.2018.02.006_bib0410
  article-title: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
  publication-title: Rheumatology (Oxf)
  doi: 10.1093/rheumatology/keq275
  contributor:
    fullname: Shima
– volume: 39
  start-page: 1294
  year: 2012
  ident: 10.1016/j.jfo.2018.02.006_bib0455
  article-title: Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
  publication-title: J Rheumatol
  doi: 10.3899/jrheum.120010
  contributor:
    fullname: Tappeiner
– volume: 176
  start-page: 301
  year: 2014
  ident: 10.1016/j.jfo.2018.02.006_bib0405
  article-title: Interleukin-6 blockade in ocular inflammatory diseases
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.12295
  contributor:
    fullname: Mesquida
– volume: 30
  start-page: 1163
  year: 2011
  ident: 10.1016/j.jfo.2018.02.006_bib0380
  article-title: Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis
  publication-title: Clin Rheumatol
  doi: 10.1007/s10067-011-1720-7
  contributor:
    fullname: Alexeeva
SSID ssj0003755
ssib019627551
ssib053390985
Score 2.2152507
SecondaryResourceType review_article
Snippet With uveitis being one of the leading causes of blindness worldwide, biological therapies have arisen as an option for the treatment of refractory cases based...
SourceID crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 759
SubjectTerms Agents biologiques
Antibodies, Monoclonal, Humanized - therapeutic use
Biologic agents
Eye Diseases - drug therapy
Humans
IL-6
Immunosuppressants
Immunosuppresseurs
Inflammation - drug therapy
Orbital Diseases - drug therapy
Tocilizumab
Treatment Outcome
Uveitis
Uvéites
Visual Acuity
Title The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative
URI https://dx.doi.org/10.1016/j.jfo.2018.02.006
https://www.ncbi.nlm.nih.gov/pubmed/30217605
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELbKIiEuiDfLSz5wYpUqqePY4RbawgIqB7ogblEc25Bq2662DRL99YxfaXaReElcrMqO43bm6_izZzxG6BnJKhLLvIqAi7LITAERl1kdwepCwv9LJoqYg8LHc_b-M59M0-lgEK6W3Nf9V01DHejanJz9C213L4UK-Aw6hxK0DuUf6z2EDG5B8qfNrl1WIsQz7gPLba4IDYBYOke7d9VsQtSA-u48C-tz0bj9w6N2o1xIs99F_HYxjshzWw3Tn_W_s6rZHMHvZ-uzr8Dxl9bOdkD60Da7aKYkPO28P8OOVNvek2oXfTI3vViz2DWO28Y0v0wc6-3qX6svtr4Im-Jvh8Wwv6eR8C46zm-0hcM2M1hAGLNZzHtmEThJBDzvgg13ybM8VnnPIDOfb9zN7czd8PLTtOF2MBbDhTbnQRPu0rheStFtJ_25Gd6MnpjEadykMLg6Ahtnokknb951JIAw6qJn_ZcNDnUbWnhpmN9Qoh7fObmJbnhl4sIh7BYaqNVtdG3mQzHuoFMAGjZAw2uNe0DDzQoDfHAHNNPeBxoOQLMd4UkAGgagYQu0F7jADma4B7O76OOr6cn4OPJXd0Q1oWQLvEfruqJZDtNFqpnkJBGKC0JTlSZ6JEWlJRW1oLGMBckrrmXKaVyNFKsTUlNyDx2s1iv1AGFJVSLqtMoVqVNJpVCpYKzmicozXsv4ED0P0ivPXIaWMoQuLkoQdWlEXcajEkR9iNIg39JTTEcdS4DCr7rdd7roRiBmLZ_F9OG_vfARur7H_WN0sD1v1RN0ZSPbpxZHUE7Hsx_OV6Ox
link.rule.ids 315,782,786,27935,27936
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+of+tocilizumab+in+the+treatment+of+inflammatory+diseases+of+the+eye+and+orbit%3A+A+useful+alternative&rft.jtitle=Journal+fran%C3%A7ais+d%27ophtalmologie&rft.au=Ruiz-Medrano%2C+J.&rft.au=D%C3%ADaz-Valle%2C+D.&rft.au=Cui%C3%B1a%2C+R.&rft.au=Geg%C3%BAndez%2C+J.A.&rft.date=2018-10-01&rft.pub=Elsevier+Masson+SAS&rft.issn=0181-5512&rft.volume=41&rft.issue=8&rft.spage=759&rft.epage=766&rft_id=info:doi/10.1016%2Fj.jfo.2018.02.006&rft.externalDocID=S0181551218302821
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0181-5512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0181-5512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0181-5512&client=summon